CN112618608A - 具有解酒功能的组合物及其制备方法和应用 - Google Patents
具有解酒功能的组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN112618608A CN112618608A CN202110062960.0A CN202110062960A CN112618608A CN 112618608 A CN112618608 A CN 112618608A CN 202110062960 A CN202110062960 A CN 202110062960A CN 112618608 A CN112618608 A CN 112618608A
- Authority
- CN
- China
- Prior art keywords
- composition
- preparation
- parts
- theanine
- dandelion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims description 29
- 230000000694 effects Effects 0.000 title abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 230000002075 anti-alcohol Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 42
- 240000008042 Zea mays Species 0.000 claims description 23
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 23
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 23
- 235000005822 corn Nutrition 0.000 claims description 23
- 102000015636 Oligopeptides Human genes 0.000 claims description 21
- 108010038807 Oligopeptides Proteins 0.000 claims description 21
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims description 20
- 244000046146 Pueraria lobata Species 0.000 claims description 17
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 17
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 238000007873 sieving Methods 0.000 claims description 15
- 241000245665 Taraxacum Species 0.000 claims description 14
- 238000010298 pulverizing process Methods 0.000 claims description 14
- 244000010000 Hovenia dulcis Species 0.000 claims description 13
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 206010019133 Hangover Diseases 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000002443 hepatoprotective effect Effects 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 abstract description 34
- 201000007930 alcohol dependence Diseases 0.000 abstract description 34
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 14
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229950006238 nadide Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 240000001949 Taraxacum officinale Species 0.000 description 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- DGIMBMZJSZEZJD-ZLELNMGESA-N (2s)-2-amino-5-(ethylamino)-5-oxopentanoic acid Chemical compound CCNC(=O)CC[C@H](N)C(O)=O.CCNC(=O)CC[C@H](N)C(O)=O DGIMBMZJSZEZJD-ZLELNMGESA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种有解酒功能的组合物及其制备方法和应用,所述组合物包括葛根、枳椇子、蒲公英、玉米低聚肽以及L‑茶氨酸。通过以上方式,本发明组合物中的各原料均为药食同源的组分和新资源食品,药性更平和,安全性高,在养心安神,理气解郁,解酒毒等方面有较好的效果,且能降低副作用,提高解酒毒的效果;本发明组合物的制备方法,工艺简单,能充分保留组合物原料中的活性成分,制备的组合物解酒效果更好。
Description
技术领域
本发明涉及食药技术领域,特别是涉及一种药食同源的具有解酒功能的组合物及其制备方法和应用。
背景技术
随着市场经济的繁荣,经常外出应酬和交友喝酒必不可少,数据统计,每年白酒消耗量达300亿公斤之多。过量饮酒会对人体造成不可逆的内脏功能障碍和智力损伤,尤其是对肝脏和大脑的损伤,并会诱发胃肠炎、高血压、肝硬化、胰腺炎等一系列疾病,甚至导致死亡。研究表明,血液中的乙醇浓度达到0.05%时,酒精的作用开始显露,出现兴奋和欣快感;当血中乙醇浓度达到0.1%时,人就会失去自制能力;如达到0.2%时,人已到了酩酊大醉的地步;达到0.4%时,人就可失去知觉,昏迷不醒,甚至有生命危险。
因此,研究开发具有解酒毒的产品,具有重要的经济意义和社会意义。目前,解酒药主要分为化学药品、中药制剂和蛋白多肽类。化学药品成分多为维生素、兴奋剂和氨基酸等,虽然能快速解酒醒酒,但很难起到护肝作用;中药制剂成分多为葛根、姜黄素、枳椇子、菊花、桑葚等,这些中药不仅副作用较小,有一定的解酒、护肝作用,但是效果较为迟缓,不能满足市场需要。蛋白多肽类解酒产品,如玉米肽、大豆肽等,安全可靠,副作用小,对乙醇脱氢酶(ADH)具有较高的激活作用,可加快乙醇的代谢,但对胃肠和大脑的保护作用欠佳。
鉴于此,本发明提供了一种新的药食同源的具有解酒功能的组合物及其制备方法和应用以解决目前存在的问题。
发明内容
基于此,本发明提供一种具有解酒功能的组合物及其制备方法和应用,所述组合物中各原料均为药食同源的组分和新资源食品,性能平和,安全性高,在解酒毒等方面有较好的效果,具有解酒毒的作用。
本发明提供了一种具有解酒功能的组合物,包括:葛根、枳椇子、蒲公英、玉米低聚肽以及L-茶氨酸。
优选的,各组分的重量分为:葛根4-20重量份、枳椇子3-15重量份、蒲公英2-10重量份、玉米低聚肽2-5重量份、L-茶氨酸0.1-0.4重量份。
优选的,各组分的重量分为:葛根6重量份、枳椇子4重量份、蒲公英3重量份、玉米低聚肽4重量份、L-茶氨酸0.35重量份。
优选的,所述组合物为内服制剂;所述内服制剂的剂型为散剂、片剂、冲剂、丸剂、乳剂、颗粒剂、胶囊剂、固体饮料或凝胶软糖。
本发明提供了一种组合物在制备具有解酒护肝的具有解酒护肝的药物、保健品和食品中的应用。
本发明还提供了一种具有解酒功能的组合物的制备方法,包括:
物料粉碎,将按比例称取干燥的葛根、枳椇子和蒲公英,粉碎过筛,获得混合后的粗末;
循环提取,加入重量为所述粗末6-12倍量的提取溶剂,加热提取,每次加热时间控制在1h-1.5h,循环提取多次;
浓缩干燥,将多次提取液合并浓缩,并减压干燥获得干膏;
制备软材,将所述干膏粉碎过筛,按比例加入玉米低聚肽以及L-茶氨酸,并与填充剂以等质量混合,喷以乙醇溶液制成软材,快速过筛后干燥灭菌即得。
优选的,所述循环提取中,加入重量为所述粗末10倍量的水,每次加热时间为1.5h,循环提取三次。
优选的,所述物料粉碎中,通过40目药典筛获得所述粗末;
和/或,所述制备软材中,填充剂为糊精,且制得的软材通过16目药典筛。
本发明还提供了一种具有解酒功能的组合物的制备方法,包括:
按比例称取葛根、枳椇子以及蒲公英,粉碎后过筛,混合干燥,加入玉米低聚肽、L-茶氨酸即得。
优选的,葛根、枳椇子以及蒲公英粉碎后通过60目药典筛。
本发明的有益效果在于提供一种有解酒功能的组合物及其制备方法和应用,所述组合物包括葛根、枳椇子、蒲公英、玉米低聚肽以及L-茶氨酸。通过以上方式,本发明组合物中的各原料均为药食同源的组分和新资源食品,药性更平和,安全性高,在养心安神,理气解郁,解酒毒等方面有较好的效果,且能降低副作用,提高解酒毒的效果;本发明组合物的制备方法,工艺简单,能充分保留组合物原料中的活性成分,制备的组合物解酒效果更好。
具体实施方式
为了便于理解本发明,下面结合具体实施方式对本发明作进一步说明。但是,本发明可以以许多不同的形式来实现,并不限于本文所描述的实施例。相反地,提供这些实施例的目的是使对本发明的公开内容的理解更加透彻全面。
除非另有定义,本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文中在本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不是旨在于限制本发明。
以上实施例的各技术特征可以进行任意的组合,为使描述简洁,未对上述实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。
本发明依据传统的中医理论,结合醉酒的发病机理和治疗原则,按中医理论组方,配伍合理,依法炮制,结合现代先进工艺制法结合而成。
本发明具有解酒功能的组合物,由以下物材组方配伍,制成制剂(按质量份计),基本配方包括:葛根4-20重量份、枳椇子3-15重量份、蒲公英2-10重量份、玉米低聚肽2-5重量份以及L-茶氨酸0.1-0.4重量份。
优选的,具有解酒功能的组合物还包括以下物质按质量份数比制成的药饵:葛根6、枳椇子4、蒲公英3、玉米低聚肽4以及L-茶氨酸0.35。
基于以上组合物,可制备成内服制剂;该内服制剂的剂型为散剂、片剂、冲剂、丸剂、乳剂、颗粒剂、胶囊剂、固体饮料或凝胶软糖。
基于以上具有解酒功能的组合物,其药理分析如下:
葛根为君药。葛根性凉味甘辛,有解表退热,生津、透疹、解酒等多种功能,自古以来被中医列为解酒专药,《本草纲目》、《千金要方》等中医著作就记载有葛根解酒保肝之功效。现代研究发现葛根的解酒作用与葛根总黄酮有关。
枳椇子为臣药,加强葛根解酒作用。枳椇子性平,味甘。归胃经,止渴除烦、清湿热、解酒毒。枳椇子是传统的解酒中药,《中国药典》及《中华本草》记载,枳椇子具有较好的解酒功能,药理研究有解酒、降压、利尿、抗脂质过氧化等作用。
蒲公英、玉米低聚肽以及L-茶氨酸(L-theanine)3味为佐药:
蒲公英性平味甘、微苦,可清热解毒、消肿散结,有“天然抗生素”之美称。蒲公英含有多种生理活性成分,如黄酮、多糖、酚类化合物、三萜、甾醇和倍半萜内酯类等。临床医学已经证实蒲公英具有保肝利胆、胃黏膜损伤修复等作用。方中蒲公英的加入可起到健胃益脾和中的作用,可减轻酒后的胃脘不适感。
玉米低聚肽是玉米蛋白经过定向酶切及特定小肽分离技术获得的小分子多肽,具有抗氧化、促进乙醇代谢、醒酒保肝、抗疲劳等作用,属于国家批准使用的新资源食品。研究结果显示玉米低聚肽的醒酒作用可能源于其可显著提高血清中丙氨酸、亮氨酸的浓度,有助于产生稳定的辅酶NAD+,故可降低血液中乙醇的浓度。
L-茶氨酸(L-theanine)是茶叶中一种独特的,非蛋白氨基酸,化学名称为N-乙基-γ-L-谷氨酰胺(N-ethyl-γ-L-glutamine),属于国家批准使用的新资源食品。L-茶氨酸对饮酒后的神经损伤具有保护作用,有实验证明,在体外培养大鼠神经细胞,并暴露在一定浓度的谷氨酸中,发现有50%的神经细胞死亡,如加入茶氨酸则神经细胞死亡数量明显减少。
基于以上具有解酒功能的组合物,本发明还提供了一种具有解酒功能的组合物的制备方法,具体包括以下步骤:
物料粉碎,将按比例称取干燥的葛根、枳椇子和蒲公英,粉碎过筛,获得混合后的粗末。
循环提取,加入重量为所述粗末6-12倍量的提取溶剂,加热提取,每次加热时间控制在1h-1.5h,循环提取多次。
浓缩干燥,将多次提取液合并浓缩,并减压干燥获得干膏。
制备软材,将所述干膏粉碎过筛,按比例加入玉米低聚肽以及L-茶氨酸,并与填充剂以等质量混合,喷以乙醇溶液制成软材,快速过筛后干燥灭菌即得。
基于以上具有解酒功能的组合物,该组合物还可应用于制备具有解酒护肝的药物、保健品和食品中。
基于以上具有解酒功能的组合物,本发明还提供了一种具有解酒功能的组合物的制备方法,具体包括以下步骤:
按比例称取上述药物,粉碎成粗末,过60目药典筛,混合均匀,干燥,加入玉米低聚肽、L-茶氨酸即可。
本发明的组合物制成的内服制剂主要用于解酒毒、护肝、养胃,用于饮酒过多或酒精性肝损伤。其用药量取决于具体剂型、患者的年龄、将康状况等因素。作为指导,用法与用量:按以上方法制成的组合物制成任何内服剂型,包装成10克/袋,使用时10克/次,1次/日,需要时服用,7天一个疗程。
实施例具有解酒功能的组合物
上述药材(玉米低聚肽、L-茶氨酸除外)经室温自然晾干后,按比例称取,粉碎成粗末,过40目药典筛,加10倍量水,每次1.5h,煎煮3次,滤液浓缩并减压干燥至恒重成干膏;干膏粉碎,过80目筛,干膏粉加入玉米低聚肽、L-茶氨酸与填充剂(糊精)以1:1比例进行混合,喷以5%,浓度为80%的乙醇溶液,制成软材后快速过16目筛,放置在60℃的鼓风干燥箱中下干燥2h-3h,灭菌,包装,每小袋10克。
通过以下试验证明本发明组合物的药理药性:
药效试验
(1)主要试剂:乙醇脱氢酶(ADH)、氧化型辅酶I(NAD+),Sigma公司。焦磷酸钠、乙醇等均为分析纯。
(2)受试物样品剂量及制备:取本发明实施例制备的组合物制剂,设置三个剂量组,按照成人(60Kg)剂量,以1倍、5倍、10倍设低、中、高3个剂量组。实验时分别称取上述颗粒剂适量,加蒸馏水溶解,定容至10ml,备用。另取硫普罗宁(Tiopronin)(成人剂量)适量,作为阳性对照组。
(3)实验方法:采用Valle&Hoch法(Vallee B L,Hoch F L.Zinc,a component ofyeast alcohol dehydrogenase[J].Proc Natl Acad Sci USA,1955,41(6):327-338)检测ADH活性。
具体步骤:
在试管中分别加入焦磷酸钠缓冲液1.5mL(pH=8.8)、0.5mL 11.5%(V:V)的乙醇溶液、1.0mL 0.027mol/L的NAD+和一定浓度的受试品溶液0.1mL,混合后放入25℃水浴中保温10min。保温结束后的试管立即加入0.1mL0.25U/mL的ADH,摇匀后立即在分光光度计340nm波长处测定吸光度值(A340nm),然后每隔15s记数一次,连续测定5min。以0.5mL蒸馏水作空白调零,以0.1mL蒸馏水代替0.1mL受试品作为空白对照组,测定空白对照组乙醇脱氢酶的酶活力。
按下式计算激活率:
激活率=(酶活力受试品试验组-酶活力空白对照组)/酶活力空白对照组×100%
(4)实验结果:实验结果见表1。
表1:组合物对乙醇脱氢酶的激活作用
注:与低剂量组和硫普罗宁组比较*p<0.01。
由表1可见,本发明实施例中组合物各剂量组及阳性对照组对ADH均有不同程度的激活作用,其中以本发明组合物的中剂量组和高剂量组激活作用最强。实验结果表明本发明组合物具有较好的解酒作用。
(5)讨论:乙醇脱氢酶(alcohol dehydrogenase,ADH)是体内参与乙醇代谢的主要酶谱,通过抑制体内对乙醇的吸收,加强乙醇在胃肠道的首过效应,从而减轻乙醇对消化系统、肝脏系统及神经系统的损害,达到解酒护肝作用。本次药效学试验结果提示,本发明组合物具有激活乙醇脱氢酶的作用,从而起到解酒的作用。
(6)结论:本发明组合物具有激活乙醇脱氢酶的作用,从而起到解酒的作用。
以上实施例仅表达了本发明的优选的实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (10)
1.一种具有解酒功能的组合物,其特征在于,包括:葛根、枳椇子、蒲公英、玉米低聚肽以及L-茶氨酸。
2.如权利要求1所述组合物,其特征在于,各组分的重量分为:葛根4-20重量份、枳椇子3-15重量份、蒲公英2-10重量份、玉米低聚肽2-5重量份、L-茶氨酸0.1-0.4重量份。
3.如权利要求1所述的组合物,其特征在于,各组分的重量分为:葛根6重量份、枳椇子4重量份、蒲公英3重量份、玉米低聚肽4重量份、L-茶氨酸0.35重量份。
4.根据权利要求1-3任一项所述组合物,其特征在于,所述组合物为内服制剂;所述内服制剂的剂型为散剂、片剂、冲剂、丸剂、乳剂、颗粒剂、胶囊剂、固体饮料或凝胶软糖。
5.根据权利要求4所述组合物在制备具有解酒护肝的药物、保健品和食品中的应用。
6.一种具有解酒功能的组合物的制备方法,其特征在于,包括:
物料粉碎,将按比例称取干燥的葛根、枳椇子和蒲公英,粉碎过筛,获得混合后的粗末;
循环提取,加入重量为所述粗末6-12倍量的提取溶剂,加热提取,每次加热时间控制在1h-1.5h,循环提取多次;
浓缩干燥,将多次提取液合并浓缩,并减压干燥获得干膏;
制备软材,将所述干膏粉碎过筛,按比例加入玉米低聚肽以及L-茶氨酸,并与填充剂以等质量混合,喷以乙醇溶液制成软材,快速过筛后干燥灭菌即得。
7.如权利要求6所述制备方法,其特征在于,所述循环提取中,加入重量为所述粗末10倍量的水,每次加热时间为1.5h,循环提取三次。
8.如权利要求6所述制备方法,其特征在于,所述物料粉碎中,通过40目药典筛获得所述粗末;
和/或,所述制备软材中,填充剂为糊精,且制得的软材通过16目药典筛。
9.一种具有解酒功能的组合物的制备方法,其特征在于,包括:
按比例称取葛根、枳椇子以及蒲公英,粉碎后过筛,混合干燥,加入玉米低聚肽、L-茶氨酸即得。
10.如权利要求9所述制备方法,其特征在于,葛根、枳椇子以及蒲公英粉碎后通过60目药典筛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110062960.0A CN112618608A (zh) | 2021-01-18 | 2021-01-18 | 具有解酒功能的组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110062960.0A CN112618608A (zh) | 2021-01-18 | 2021-01-18 | 具有解酒功能的组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112618608A true CN112618608A (zh) | 2021-04-09 |
Family
ID=75294487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110062960.0A Pending CN112618608A (zh) | 2021-01-18 | 2021-01-18 | 具有解酒功能的组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112618608A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113995073A (zh) * | 2021-11-19 | 2022-02-01 | 浙江澳兴生物科技有限公司 | 一种固体醒酒饮料 |
CN114917278A (zh) * | 2022-07-11 | 2022-08-19 | 上海诺德生物实业有限公司 | 一种护肝组合物的配方及制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050105781A (ko) * | 2004-05-03 | 2005-11-08 | 이승도 | 숙취해소용 조성물 및 이를 유효성분으로 함유하는건강보조식품 |
CN109699797A (zh) * | 2019-02-22 | 2019-05-03 | 广州市人健生物科技有限公司 | 一种具有解酒效果的玉米低聚肽压片糖果及其制备工艺 |
CN111642614A (zh) * | 2020-06-04 | 2020-09-11 | 舜朵(德州)医药科技有限公司 | 一种解酒的压片糖果及其制备方法 |
CN111870627A (zh) * | 2020-09-15 | 2020-11-03 | 河南融易健康科技有限公司 | 一种解酒制剂及其制备方法和用途 |
-
2021
- 2021-01-18 CN CN202110062960.0A patent/CN112618608A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050105781A (ko) * | 2004-05-03 | 2005-11-08 | 이승도 | 숙취해소용 조성물 및 이를 유효성분으로 함유하는건강보조식품 |
CN109699797A (zh) * | 2019-02-22 | 2019-05-03 | 广州市人健生物科技有限公司 | 一种具有解酒效果的玉米低聚肽压片糖果及其制备工艺 |
CN111642614A (zh) * | 2020-06-04 | 2020-09-11 | 舜朵(德州)医药科技有限公司 | 一种解酒的压片糖果及其制备方法 |
CN111870627A (zh) * | 2020-09-15 | 2020-11-03 | 河南融易健康科技有限公司 | 一种解酒制剂及其制备方法和用途 |
Non-Patent Citations (3)
Title |
---|
刘冰: "L-茶氨酸药理作用的研究进展", 《神经药理学报》 * |
刘旭峰: "《生活中的化学》", 31 August 2019, 中国纺织出版社有限公司 * |
李桂兰: "L-茶氨酸对H2O2致L02细胞损伤的保护作用及其机制研究", 《中国细胞生物学学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113995073A (zh) * | 2021-11-19 | 2022-02-01 | 浙江澳兴生物科技有限公司 | 一种固体醒酒饮料 |
CN114917278A (zh) * | 2022-07-11 | 2022-08-19 | 上海诺德生物实业有限公司 | 一种护肝组合物的配方及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103784611B (zh) | 一种具有改善睡眠帮助缓解压力的组合物及其应用 | |
CN106975069B (zh) | 一种保肝护肝组合物及其制备方法 | |
US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
CN107233442B (zh) | 一种具有改善痛风不适症状的组合物及指纹图谱建立方法 | |
CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
CN112618608A (zh) | 具有解酒功能的组合物及其制备方法和应用 | |
CN112690450A (zh) | 解酒护肝的组合物及其制备方法和包含其的产品 | |
CN105707637A (zh) | 一种降糖固体饮料及其制备方法 | |
CN107853517A (zh) | 一种提神抗疲劳的中药饮料及其制备方法 | |
CN110934976A (zh) | 一种治疗近视的药物及其制备方法 | |
CN108813501A (zh) | 具有清热润肺止咳化痰平喘和调节人体机能的养生蜂蜜膏 | |
CN103142916B (zh) | 一种预防和治疗老年性痴呆病的药物 | |
CN107836619A (zh) | 一种具有增强免疫力和抗疲劳作用的牛大力固体饮料及其制备方法 | |
CN111870627A (zh) | 一种解酒制剂及其制备方法和用途 | |
CN116898098A (zh) | 一种牛肝肽解酒配方及原料制备方法 | |
CN106266811B (zh) | 一种用于改善化学性肝损伤的中药组合物及其制备方法和应用 | |
CN103005436B (zh) | 一种桑资源辅助降血糖保健食品及其制备方法 | |
CN105876783A (zh) | 一种铁皮石斛花组合物及其制法和保肝解酒制品 | |
WO2012016384A1 (zh) | 一种具有抗疲劳功效的植物原料组合物及其制备方法、用途和产品 | |
CN107439866A (zh) | 枸杞鹰嘴豆植物营养素饮料及其制备工艺 | |
CN112674338A (zh) | 具有抗疲劳功效的组合物及其制备方法和应用 | |
CN106387915B (zh) | 杞咖益元泡腾片及其制备工艺和应用 | |
CN101554233B (zh) | 西归功能性食品 | |
CN105597083B (zh) | 一种对肝肾有辅助保护作用的保健食品及其制备方法 | |
CN115737747B (zh) | 一种用于改善记忆力、防治老年痴呆的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210409 |
|
RJ01 | Rejection of invention patent application after publication |